HONOLULU--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two 26-week investigational Phase III clinical studies evaluating the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback